TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
114.00
+4.80 (4.40%)
At close: Apr 10, 2026, 4:00 PM EDT
112.24
-1.76 (-1.54%)
Pre-market: Apr 13, 2026, 4:06 AM EDT
TransMedics Group Employees
TransMedics Group had 898 employees as of December 31, 2025. The number of employees increased by 170 or 23.35% compared to the previous year.
Employees
898
Change (1Y)
170
Growth (1Y)
23.35%
Revenue / Employee
$674,269
Profits / Employee
$211,905
Market Cap
3.91B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 898 | 170 | 23.35% |
| Dec 31, 2024 | 728 | 144 | 24.66% |
| Dec 31, 2023 | 584 | 372 | 175.47% |
| Dec 31, 2022 | 212 | 64 | 43.24% |
| Dec 31, 2021 | 148 | 38 | 34.55% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 29, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 29, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 29, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bruker | 11,085 |
| Integer Holdings | 11,000 |
| Bio-Rad Laboratories | 7,450 |
| Bio-Rad Laboratories | 7,450 |
| LivaNova | 3,300 |
| Haemonetics | 3,023 |
| Neogen | 2,974 |
| iRhythm Holdings | 2,400 |
TMDX News
- 6 weeks ago - TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results - PRNewsWire
- 6 weeks ago - TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 7 weeks ago - TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 7 weeks ago - TransMedics to Present at Upcoming March Investor Conferences - PRNewsWire
- 2 months ago - TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - PRNewsWire
- 2 months ago - TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial - PRNewsWire
- 2 months ago - These 10 Stocks Could Be Short Squeeze Targets: Lucid, Kohl's, Avis and More - Benzinga
- 3 months ago - These under-the-radar stocks combine fast growth with big upside potential - Market Watch